Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study-Reference-Cited by-同舟云学术

Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study

Published:2024-01-06 Issue:4 Volume:31 Page:348-348
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J of Urology

Author:

Taguchi Satoru¹^ORCID

Affiliation:

1. Department of Urology, Graduate School of Medicine The University of Tokyo Tokyo Japan

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.15387

Reference5 articles.

1. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

2. Enfortumab vedotin versus platinum rechallenge in post‐platinum, post‐pembrolizumab advanced urothelial carcinoma: A multicenter propensity score‐matched study

3. Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort

4. Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study

5. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence;Life Sciences;2024-09